Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't know, still hoping. Fingers crossed.
Yes I know, still waiting for those filings.
FCIC new CEO is also CEO of CLAD https://www.otcmarkets.com/stock/CLAD/profile
FCIC finally 8k with change if control
8k, rm with VeganNation https://vegannation.io/
Amended 10k out, now the other officers are added
Still going up. 25 shares traded at 165 and 10 at 170
sure can
I'm quite sure it is, LinkedIn profile says public company https://www.linkedin.com/company/aibit/about/
TGCB looks like it will go .7 x 1.00
No, I don't
Like it too, so couldn't resist
Took some TGCB, started trading yesterday
It has been CE for a long time, but I guess it will be removed after they are up to date
2500 bidder at 4.05 now
yeah, lol. I'm out now
He got a trademark too https://trademarks.justia.com/885/88/waterwood-88588512.html
8 April 2021, Palm Beach, Florida
Signet CEO Suffers Apparent Stroke, Contingency Operational Plans Underway
Ernest Letiziano, CEO of Signet International Holdings, Inc. (OTC “SIGN’), suffered an apparent stroke this week. The severity and prognosis of his condition is currently being evaluated. Contingency operational plans are being evaluated and will be made public as soon as they are finalized.
http://www.signetinternationalholdings.com/news/
We want you to also experience the excitement and join our growing family. We have set aside a limited amount of shares for private placements. And we will soon announce our IPO!
https://timberwisegroup.com/about
Great!
Definitely CBGH will carry on its M&A plan, and Management is confident that the Pubco's future is very promising!!!
Definitely CBGH will carry on its M&A plan, and Management is confident that the Pubco's future is very promising!!!
— CBGH (@cbgholding) April 6, 2021
Neon Bloom, Inc. (NBCO) Partners with World Leader in Genome Engineering for further development of THC Free Cannabis StrainsPress Release | 04/01/2021
Neon Bloom, Inc. (NBCO) Partners with World Leader in Genome Engineering for further development of THC Free Cannabis Strains
PR Newswire
ORLANDO, Fla., April 1, 2021
ORLANDO, Fla., April 1, 2021 /PRNewswire/ -- Neon Bloom, Inc. (OTC: NBCO) NBCO's subsidiary, Bazelet Health Systems, Inc. and Oglesby Plants International, Inc. formed an LLC to jointly Develop, Cultivate and Market Advanced Exclusive Strains of THC Free Cannabis for Medical & Consumer Markets.
Bazelet is an American company leading the world in THC Free Cannabis (0.00% tetrahydrocannabinol) plant genetics, purpose-built for fiber and grain production and cannabinoid derived food, drug and cosmetic products. Bazelet also operates cERI, the cannabis Education and Research Initiative providing accredited education for undergraduates, physicians, farmers, and regulated industries coupled with a robust scientific platform conducting fundamental, applied and clinical research. #Bazelet (PRNewsfoto/Bazelet Health)
NBCO, a company that focuses on enhancement and creation of genetic intellectual property in the cannabis industry to develop effective medical and health/wellness products, announced today that its wholly owned subsidiary Bazelet Health Systems, Inc. (BHS) and Florida based Oglesby Plants International, Inc. (OPI) formed jointly owned Bazelet Oglesby, LLC. (BO).
Bazelet Oglesby is a plant science company that is commercializing the world's first THC/CBD Free Cannabis plant varieties for use in future food, beverage, OTC and pharmaceutical products. BO is owned by Bazelet Health Systems, Inc., a world leader in the specialized study and science of the Cannabis Sativa L plant. BHS and its scientific partners have broken the code in plant genome editing allowing the company unbridled innovation of safe, very effective, THC/CBD Free cannabis and Oglesby Plants International, founded in 1947 is one of Florida's premier horticulture companies and a recognized world leader in plant tissue culture propagation and manufacturer of high quality (young) ornamental plants.
Bazelet Oglesby operates from OPI's Altha, Florida campus that features more than 200,000 square feet of modern plant laboratory and manufacturing facilities with over $4M in recent capital improvements and well-trained employees ready to make Bazelet Oglesby built THC Free cannabis plants.
"Our new company is comprised of a global team of horticultural specialists that bring a host of science-based solutions, knowledge, and experience in plant physiology, plant health, plant production, plant products, and sustainable agriculture." said Gary Hennen, President of Oglesby Plants International. Mr. Hennen went on to say "Bazelet Oglesby is one of only a few companies positioned to establish legal cannabis as a respected, sustainable industry. We are honored and accept with responsibility that we are part of authoring its history."
"Bazelet Oglesby will immediately lead the plant science community developing elite strains of THC and CBD Free cannabis that support regional growing environments and create long-term demand for new plant-derived ingredients for foods, pharmaceuticals, and other natural products." said David Grand, Bazelet co-founder and Director of Research.
About Neon Bloom, Inc.
Neon Bloom, Inc. (OTC: NBCO), wholly owns Bazelet Health Systems, Inc. (BHS). BHS is the global forefront of the legal cannabis industry and has three operating subsidiaries: Bazelet Oglesby, Bazelet Research & Innovation, and Bazelet Learning.
RDGA, shell since 2000, in 2 days from 2.82 to 9.25 with some volume after this 8k:
News out https://www.newsfilecorp.com/release/78333
QuantGate Systems Inc. Launches Crypto Division: QuantGate Crypto
New York, New York and Toronto, Ontario--(Newsfile Corp. - March 23, 2021) - QuantGate Systems Inc. (OTCQB: QGSI) (the "Company"), an Artificial Intelligence ("AI") and Machine Learning ("ML") SaaS based solutions provider, is pleased to announce the launch of QuantGate Crypto, a wholly-owned division of the Company, focused on providing a highly intelligent, SaaS based technology solution for various crypto companies, institutions and platform providers.
Launching this new division is a major first step in QuantGate's expansion into the cryptocurrency market, which is inherently volatile and complex, and in dire need of unbiased, performance enhancing solutions such as those provided by QuantGate Crypto.
Ilan Yosef, CTO/COO of QuantGate, states: "The focus of QuantGate Crypto is to significantly enhance cryptocurrency platforms and exchanges, by integrating our ground-breaking technology. Our proprietary SaaS solutions and artificial intelligence algorithms are perfectly suited to the dynamic cryptocurrency markets, having already been applied and proven with Forex and Stocks. We are committed to enhance the wide array of blockchain offerings, which includes providing turn-key solutions to serve a rapidly growing market."
Mr. Yosef further comments: "QuantGate takes the "speculation" out of investing by being able to anticipate the upcoming price behaviour of cryptocurrencies. Our proprietary algorithms, augmented with AI and machine learning, enhance our capability and intelligence to deliver on our primary mission - anticipate in real time where the market is heading!"
QuantGate Crypto will add unique crypto capabilities to QuantGate's core solutions platform. This includes robust smart-order-routing technology to provide best price and execution as well as a variety of turn-key solutions. The first application of its' cryptocurrency intelligent capabilities is already in progress with the development of "Crypto Nuvo", a mobile crypto application powered by QuantGate's algorithms and mobile SaaS infrastructure. Scheduled to launch in Q2 2021, investors can join a waitlist https://cryptonuvo.com/.
Crypto Nuvo will offer the following features:
Smart order routing technology connects to multiple exchanges and liquidity providers for access to more liquidity and better trade execution
Secure and compliant infrastructure
End-to-end solution enables integration with crypto wallet and custody solutions
Advanced investment features, portfolio management and position monitoring
Instant funding and trading of crypto assets with zero-commissions
Powered by AI to enhance both novice and advanced investor opportunities
About QuantGate Systems Inc.
QuantGate System Inc. (OTCQB: QGSI) (www.quantgatesystems.com) is a fintech company operating for 10+ years, developing sophisticated Artificial Intelligence (AI), Machine Learning (ML) and proprietary big-data processing algorithms to deliver SaaS solutions and seamless API integration. Our core intelligence identifies investment opportunities across multiple asset classes, rooted in the financial markets, and perfected for cryptocurrency exchanges, enabling our valued clients to make better informed investment decisions. Turnkey solutions and efficient API's, founded on robust and scalable SaaS architecture, easily allow 3rd party integration for onboarding existing users, and scaling globally.
Huge volume coming in
Saw that
Nothing to find about it
sure, waiting for 8k/name change on DL
Name change filed on DE SOS to Universal Global Hub
Gaensel Energy Group, Inc. (GEGR) Acquires SSCB Swiss Stem Cells Biotech, the Only Private Stem Cell Biobank in Switzerland
Newsfile Corp.
Newsfile Corp
Salt Lake City, Utah--(Newsfile Corp. - March 17, 2021) - Gaensel Energy Group, Inc. (OTC Pink: GEGR) Board of Directors announce today the completion of the agreements for the acquisition of SSCB Swiss Stem Cells Biotech SA.
Gaensel Energy Group, Inc.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7475/77566_d11048e994f20a54_001full.jpg
Swiss Stem Cells Biotech
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7475/77566_d11048e994f20a54_002full.jpg
The Company is pleased to announce the first of at least 2 acquisitions in the Biotech Industry.
SSCB is a world renowned participant in Stem Cell Technology and places Gaensel in the front of this exciting and revolutionary health technology.
The Board expressed its pleasure working with the President Claudio Massa where he and his advisors have worked tirelessly over the past ninety days to ensure the success of the negotiations and final agreements being completed. The Shareholders of Gaensel will see the long term value this new partnership brings to the Company.
ABOUT SSCB
SSCB Swiss Stem Cells Biotech SA is a Biotech Company; SSCB was born in 2005 as a spin-off of Cardiocentro Ticino of Lugano - Switzerland and is also present with other offices in Italy, Spain, Albania and Balkan countries.
SSCB was founded as a private bank for the cryopreservation of human stem cells obtained from blood and cord tissue for both autologous and allogeneic intra-family use.
SSCB also allows the preservation of stem cells from adipose tissue. These cells have great potential in regenerative medicine, thanks to their ability to differentiate into numerous cell types and thus reconstruct many compromised tissues and organs.
SSCB operates in the field of cellular therapies with specialization in the collection, purification, characterization, processing and storage of stem cells for therapeutic and aesthetic uses and for the development of new experimental protocols.
Thanks to the constant commitment in biotechnology in the cellular field, over the years a highly specialized know-how and cutting-edge methods have been developed in the processes, quality and safety of storage and release of stem cells.
The headquarters in Vacallo, Switzerland, is a complete and self-sufficient structure of 1,600 square meters. It houses the bio-bank, the Laboratories for processing and characterization of samples, Scientific Direction, Quality Control laboratory, Quality Assurance Department, Medical Direction, Administration and Customer Care. Through these functions it guarantees the direct and complete management of all the phases of the relationship with the final customer, also guaranteeing him a unique logistic reference.
THE EXCELLENCE OF SSCB
SSCB adheres to the strictest guidelines specific to the field of cellular therapies and therapeutic agents. This makes SSCB a highly specialized and cutting-edge company in the field, able to process, store and release safe and certified samples.
SSCB has been the first private bio-bank in Europe to be certified since 2012 by FACT-NetCord, the specific accreditation for cord blood banks. This accreditation places SSCB at the same quality levels as public cord blood bio-banks.
In 2014, SSCB obtained the validation of the protocols for the extraction of stem cells from adipose tissue (SVF-Stromal Vascular Fraction).
SSCB is recognized and listed in the 2019 World Marrow Donor Association (WMDA) registry (https://share.wmda.info/display/WMDAREG/Database#) as a private biobank capable of processing and releasing donation samples.
In 2020, SSCB was chosen as the only private biobank by the Swiss Federal Office of Public Health in the Public-Private Hybrid Bank project.
SSCB receives regular inspections by SwissMedic, Swiss Institute for Therapeutic Products, and FACT-NetCord to process and store stem cells in their laboratories.
SwissMedic, through their inspections of our processes and laboratories, ensures the quality of the methods and protocols that SSCB performs: from logistics to sample release.
Moreover, in 2020 SSCB Laboratories have been certified GMP, (Good Manufacturing Practices) obtaining the qualification to produce pharmaceutical products based on stem cells.
To support the quality and safety applied to processing and preservation techniques, SSCB employs international personnel, highly trained and qualified in the most modern preservation techniques applied to regenerative therapies.
SWISS STEM CELL FOUNDATION AND FREE ADVICE ON INTERNATIONAL CLINICAL TRIALS
The (SSCF) Swiss Stem Cell Foundation (https://sscf.ch/), is a independent and non-profit, collaborates with SSCB and has as its goal the research and development in the field of stem cells, the development of new cell therapies in the human field based on stem cells, as well as the training, consulting and dissemination of knowledge in this field to professionals and the public.
SSCB also collaborates with prestigious international hospitals in the treatment of patients affected by diseases subject to clinical trials and supports parents who have relied on the conservation of their children's stem cells. Thanks to the collaboration with, for example, Duke University in North Carolina and the University Hospital of Monterrey in Mexico, SSCB has released stem cell samples successfully used for the treatment of two separate cases of cerebral palsy.
WHAT SSCB DOES
Our Bio-bank has a capacity to cryopreserve a wide range of biological materials:
Bio-bank of Cells, Tissues and DNA
Cord blood stem cells
Cord tissue stem cells
Adipose tissue stem cells
Peripheral Blood Conservation
Preservation of Plasma and Serum
DNA storage
The cryopreservation of cells is carried out both in liquid nitrogen and nitrogen vapors, depending on the biological material to be stored to guarantee its highest quality and safety
Research and Development
Development of stem cell extraction protocols from different sources
Development of tissue preservation protocols
Development of protocols for the preparation of PRP, PDGF and PRGF
Translation of search protocols into GMP
Research Training and Development for Regenerative Medicine
Development of clinical protocols for the use of stem cells
Preparation of IMPD and documentation for the Ethics Committee
Partners in clinical trials using stem cells
Development of anti-aging therapies
Basic and advanced training courses to support regenerative medicine and new application frontiers in this field
Consulting
Recruitment advice in international clinical trials
Advice in the field of personalized medicine
Predictive genetics
Prenatal genetic testing
Genetic tests on cord blood
Anti-aging genetic testing
Nutrigenomic genetic tests
Microbiome test
SSCB - SWISS STEM CELLS BIOTECH SAVia Pizzamiglio, 12 - 6833 Vacallo - Switzerland
Offices in: Italy, Spain, Albania, Balkan countries
https://www.sscb-stembiotech.com/
About Gaensel Energy Group, Inc. (OTC Pink: GEGR):
Gaensel Energy Group asset base currently consists of proven companies in Biotech, Commodities, Apparrel - Fashion, Green and Renewable Energy, and Technology. The management teams for each of these divisions are actively seeking similar partners in each space for expansion and additional acquisitions. We have been listed on the United States OTC Markets since 2002 and the Company is current.
Gaensel Energy Group, Inc.
57 West 200 South
Suite 300
Salt Lake City, UT 84101
admin@gegrgroup.com
Phone: +1 518-567-3649
https://www.gegrgroup.com
I wish I knew!
Actually made a mistake. .2-.5099 is 2500, 51-.9999 is 1000
00001-.0999 is 10k, .1-.1999 is 5k, .2-.9999 is 2500 and above 1 is 100, everything below doesn't show up.
CINV few buys at 8.00
No, I have enough.
About
1. Experiencing in the Initial Public Offering (IPO) and Merge & Acquisition (M&A);
2. Strong knowledge of the Hong Kong and PRC listing requirements in Main Board, Small and Medium Enterprise Board (SME Board), Growth Enterprise Market Board (GEM Board) and New Over-The-Counter Market Board (New OTC Market Board);
3. Experiencing in negotiating and maintaining the relationships with auditors, securities dealers, private equity investors, lawyers, major customers and suppliers;
4. Experiencing in negotiation of fund raising and having good connections with the bankers on hand;
5. Experiencing in financial planning and analysis (FP&A) and cash flow management of aquaculture and property development projects;
6. Experiencing in consolidation and regional management reporting;
7. Experiencing in handling Hong Kong and PRC tax filing, queries and planning;
8. Experiencing in monitoring and coordinating with different regional accounting departments;
9. Understanding different internal control system from medium to large size companies and experiencing in the improvement and implementation of internal control and corporate governance;
10. Exposures of taking charges of ad hoc corporate transactions and special projects;
11. Audit exposures in various fields in the listed companies in Hong Kong and PRC; and
12. Knowledge in Microsoft office and PRC accounting software of ?? and ????.